Skip to content
Shorla Oncology: A Leader in Innovative Oncology Solutions
  • About Us
    • Executive Team
    • Leadership Team
    • Board of Directors
    • Advisory Team
  • Products
    • TEPYLUTE
    • IMKELDI
    • JYLAMVO
    • Nelarabine Injection
  • Pipeline
  • News
    • Company Updates
    • Media
  • Careers
  • Contact

Media

Shorla Oncology

FDA Approves Tepylute for Breast and Ovarian Cancer Treatment

February 20th 2025July 2nd 2024

Read More

FDA

FDA approves Shorla Oncology’s TEPYLUTE for cancer treatment

February 20th 2025July 2nd 2024

Read More

Photo

A Milestone for Shorla Oncology

April 22nd 2024

Read More

Logo

FDA Considers SH-201 for Treating Certain Leukemias and Cancers

April 22nd 2024

Read More

Oncology Live Logo

FDA Accepts NDA for SH-201 in Leukemia and Other Cancers

July 18th 2025April 22nd 2024

Read More

Logo

FDA Accepts Shorla’s NDA for SH-201 to Treat Leukemia and Other Cancers

April 22nd 2024

Read More

Logo

FDA Receives New Drug Application for SH-105 in Breast and Ovarian Cancer

January 15th 2024January 15th 2024

Read More

Logo

OncLive/ SH-105 Gets Accepted for FDA Review in Breast and Ovarian Cancer

January 15th 2024January 15th 2024

Read More

Logo

Targeted Oncology/ FDA Ok’s NDA for SH-105 in Breast and Ovarian Cancer

January 15th 2024January 15th 2024

Read More

Older posts
Newer posts
Page1 … Page3 Page4 Page5 … Page7
Logo

IRELAND HQ:
Questum Acceleration Center,
Ballingarrane Science & Technology Park,
Clonmel, Co. Tipperary,
E91 V329, Ireland

Shorla Pharma Ltd trading as Shorla Oncology®

All trademarks are the property of their respective owners.

US OFFICE:
245 Main St.,
2nd floor,
Cambridge,
MA 02142, USA

SITEMAP

PRIVACY POLICY

STATE COMPLIANCE PROGRAM DECLARATIONS

Company number: 618033
©SHORLA ONCOLOGY® 2026

© 2026 Shorla Oncology: A Leader in Innovative Oncology Solutions • Built with GeneratePress
  • About Us
    • Executive Team
    • Leadership Team
    • Board of Directors
    • Advisory Team
  • Products
    • TEPYLUTE
    • IMKELDI
    • JYLAMVO
    • Nelarabine Injection
  • Pipeline
  • News
    • Company Updates
    • Media
  • Careers
  • Contact

Now approved for use in Pediatrics

  • Treatment of pediatric patients with polyarticular juvenile idiopathic arthritis (pJIA).
  • Treatment of pediatric patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen.

Please click here for the full Prescribing information, including Boxed Warning regarding embryo-fetal toxicity, hypersensitivity reactions, and severe adverse reactions.